AR103624A1 - Composiciones farmacéuticas para terapia de combinación - Google Patents

Composiciones farmacéuticas para terapia de combinación

Info

Publication number
AR103624A1
AR103624A1 ARP160100332A ARP160100332A AR103624A1 AR 103624 A1 AR103624 A1 AR 103624A1 AR P160100332 A ARP160100332 A AR P160100332A AR P160100332 A ARP160100332 A AR P160100332A AR 103624 A1 AR103624 A1 AR 103624A1
Authority
AR
Argentina
Prior art keywords
phenyl
methyl
ppar
pharmaceutical composition
agonist
Prior art date
Application number
ARP160100332A
Other languages
English (en)
Inventor
Adorini Luciano
Pruzanski Mark
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR103624(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of AR103624A1 publication Critical patent/AR103624A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende un agonista del FXR, al menos un agonista del PPAR-a, un agonista del PPAR-d y/o un agonista doble del PPAR-a y del PPAR-d y opcionalmente uno o más vehículos farmacéuticamente aceptables. Reivindicación 2: La composición farmacéutica de acuerdo con la reivindicación 1, donde el al menos un agonista del PPAR-a es un fibrato. Reivindicación 3: La composición farmacéutica de acuerdo con la reivindicación 2, donde el fibrato se selecciona entre el bezafibrato, el ciprofibrato, el clofibrato, el fenofibrato, el gemfibrozil, el binifibrato, el clinofibrato, el ácido clofíbrico, el nicofibrato, el pirifibrato, el plafibride, el ronifibrato, el teofibrato, el tocofibrato, las sales farmacéuticamente aceptables de cualquiera de éstos, los ésteres farmacéuticamente aceptables de cualquiera de éstos y los derivados del ácido 2-fenoxi-2-metilpropanoico en los cuales la unidad de fenoxilo ha sido sustituida con una piperidina, una 4-hidroxipiperidina, unas piperazina o un piperid-3-eno opcionalmente sustituido. Reivindicación 7: La composición farmacéutica de acuerdo con la reivindicación 1, donde el al menos un agonista del PPAR-d es el ácido {4-[({4-metil-2-[4-(trifluorometil)fenil]-1,3-tiazol-5-il}metil)sulfanil]-2-metilfenoxi}acético, el ácido {2-metil-4-[5-metil-2-(4-trifluorometil-fenil)-2H-[1,2,3]triazol-4-ilmetilsilfanil]-fenoxi}-acético, el ácido [4-[[[2-[3-fluoro-4-(trifluorometil)fenil]-4-metil-5-tiazolil]metil]tio]-2-metilfenoxi]-acético o una sal farmacéuticamente aceptable de cualquiera de éstos. Reivindicación 8: La composición farmacéutica de acuerdo con la reivindicación 1, donde el al menos un agonista doble del PPAR-a y del PPAR-d es el ácido 2-[2,6-dimetil-4-[3-[4-(metiltio)fenil]-3-oxo-1(E)-propenil]fenoxil]-2-metilpropanoico, el ácido (2S)-2-metoxi-3-[4-[2-(5-metil-2-fenil-4-oxazolil)etoxi]-7-benzotiofenil]propanoico, la N-[(4-metoxifenoxi)carbonil]-N-{4-[2-(5-metil-2-fenil-1,3-oxazol-4-il)etoxi]bencil}glicina, el ácido (2S)-2-etoxi-3-[4-[2-(4-metilsulfoniloxifenil)etoxi]fenil]propanoico, el ácido (2S)-2-etoxi-3-[4-(2-{2-metil-5-[4-(metilsulfanil)fenil]-1H-pirrol-1-il}etoxi)fenil]propanoico o una sal farmacéuticamente aceptable de cualquiera de éstos. Reivindicación 9: La composición farmacéutica de acuerdo con la reivindicación 1, que también comprende una estatina. Reivindicación 10: La composición farmacéutica de acuerdo con la reivindicación 9, donde la estatina se selecciona entre la simvastatina, la fluvastatina, la pravastatina, la rivastatina, la mevastatina, la atorvastatina, la cerivastatina, la lovastatina, la pitavastatina, la fluinadostatina, la velostatina, la dalvastatina, la rosuvastatina, la dihidrocompactina y la compactina. Reivindicación 12: La composición farmacéutica de acuerdo con la reivindicación 1, 9 u 11, donde el agonista del FXR es un compuesto que responde a la fórmula (1), una sal farmacéuticamente aceptable de éste o un conjugado de éste con un aminoácido, donde R¹ es hidrógeno o un alquilo C₁₋₆ no sustituido; R² es hidrógeno o a-hidroxilo; X es C(O)OH, C(O)NH(CH₂)ₘSO₃H, C(O)NH(CH₂)ₙCO₂H u OSO₃H; R⁴ es hidroxilo o hidrógeno; R⁷ es hidroxilo o hidrógeno; m es 1, 2 ó 3; y n es 1, 2 ó 3.
ARP160100332A 2015-02-06 2016-02-05 Composiciones farmacéuticas para terapia de combinación AR103624A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06

Publications (1)

Publication Number Publication Date
AR103624A1 true AR103624A1 (es) 2017-05-24

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100332A AR103624A1 (es) 2015-02-06 2016-02-05 Composiciones farmacéuticas para terapia de combinación

Country Status (30)

Country Link
US (3) US11311557B2 (es)
EP (2) EP4035665A1 (es)
JP (2) JP7306791B2 (es)
KR (1) KR20170115071A (es)
CN (1) CN107405325B (es)
AR (1) AR103624A1 (es)
AU (2) AU2016215179B2 (es)
BR (1) BR112017016766B1 (es)
CA (1) CA2976056C (es)
CL (3) CL2017001983A1 (es)
CO (1) CO2017007959A2 (es)
CR (1) CR20170356A (es)
DK (1) DK3253382T3 (es)
EA (1) EA036404B1 (es)
EC (1) ECSP17057848A (es)
ES (1) ES2905872T3 (es)
GT (1) GT201700174A (es)
IL (2) IL253719B (es)
MA (1) MA40814A1 (es)
MX (1) MX388508B (es)
NI (1) NI201700100A (es)
PE (1) PE20180027A1 (es)
PH (1) PH12017501384A1 (es)
SG (1) SG11201706347SA (es)
SV (1) SV2017005512A (es)
TN (1) TN2017000344A1 (es)
TW (1) TW201628625A (es)
UA (1) UA125744C2 (es)
WO (1) WO2016127019A2 (es)
ZA (1) ZA201706007B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103624A1 (es) 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
ES2974281T3 (es) 2015-04-07 2024-06-26 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
CN108350020A (zh) * 2015-09-24 2018-07-31 英特塞普特医药品公司 用于制备胆汁酸衍生物的方法和中间体
MX2021015783A (es) * 2016-03-31 2022-12-09 Genfit Metodos de tratamiento de enfermedades colestaticas.
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Ltd composição farmacêutica e método para o tratamento de colangite biliar primária
KR20190117632A (ko) * 2017-02-21 2019-10-16 장피트 Ppar 효현제와 fxr 효현제의 병용
US20190076500A1 (en) * 2017-09-13 2019-03-14 Novartis Ag Combinations comprising fxr agonists
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
BR112021020234A2 (pt) * 2019-04-10 2021-12-07 Genfit Terapia de combinação que compreende compostos da fórmula (i) e agonistas de receptor de glp-1
WO2020243590A1 (en) * 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
CA3139291A1 (en) * 2019-07-18 2021-01-21 Jacky Vonderscher Method for decreasing adverse-effects of interferon
EP4031124A4 (en) * 2019-09-20 2024-01-24 Reneo Pharmaceuticals, Inc. Use of a ppar-delta agonist in the treatment of kidney disease
JP2023502396A (ja) * 2019-11-22 2023-01-24 アヴォリント 原発性胆汁性胆管炎を処置するためのｓｇｌｔ２阻害剤の使用
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
US20250161326A1 (en) * 2022-01-28 2025-05-22 Intercept Pharmaceuticals, Inc. Combination therapy
WO2024132001A1 (en) * 2022-12-21 2024-06-27 Charles University, Faculty Of Pharmacy In Hradec Kralove Multitarget nuclear receptor ligands based on 2-(4-(quinolin-2-yloxy)phenoxy)propanoic acid and 2-(4-(quinoxalin-2-yloxy)phenoxy)propanoic acid for the treatment of metabolic and liver diseases

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (es) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
US3716583A (en) 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (es) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (es) 1973-07-05 1977-07-15 Roussel Uclaf
ES8101585A1 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE69329894T2 (de) 1992-12-08 2001-05-03 Ss Pharmaceutical Co., Ltd. Arylamidderivate
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1019059A4 (en) 1997-01-24 2004-01-14 Univ California USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE
HUP0003103A3 (en) * 1997-08-29 2002-03-28 Pfizer Prod Inc Combination therapy comprising amlodipine and a statin compound
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
EP1140036A2 (en) 1998-12-18 2001-10-10 Abbott Laboratories Novel formulations comprising lipid-regulating agents
CA2356887A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
JP2003531171A (ja) 2000-04-19 2003-10-21 トーマス ジュリアス ボロディー 高脂血症関連疾患に対する組成物および治療
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
AU2002211216A1 (en) 2000-09-18 2002-04-02 Glaxo Group Limited Substituted aminopropoxyaryl derivatives useful as agonists for lxr
IL157816A0 (en) 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
GB0405349D0 (en) * 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
ES2533993T3 (es) 2004-03-12 2015-04-16 Intercept Pharmaceuticals, Inc. Tratamiento de fibrosis usando ligandos de FXR
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
US20090131395A1 (en) 2005-05-05 2009-05-21 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
CN101534641A (zh) * 2006-03-22 2009-09-16 哈佛大学校长及研究员协会 治疗高胆固醇血症和动脉粥样硬化的方法和组合物
CN101448791B (zh) 2006-05-24 2011-11-16 伊莱利利公司 Fxr激动剂
PE20080259A1 (es) 2006-05-24 2008-04-10 Lilly Co Eli Compuestos y metodos para modular fxr
SI2040713T1 (sl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals, Inc. Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
BRPI0621942A2 (pt) 2006-08-04 2011-10-18 Aska Pharm Co Ltd preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
US7998995B2 (en) 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SI2641596T1 (sl) * 2009-11-26 2018-09-28 Genfit Uporaba 1,3-difenilprop-2-en-1-on derivatov za zdravljenje motenj jeter
DK3336097T3 (da) 2012-06-19 2020-09-28 Intercept Pharmaceuticals Inc Fremstilling af ikke-krystallinsk obeticholsyre
NZ707389A (en) 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
MX352065B (es) 2013-05-14 2017-11-08 Intercept Pharmaceuticals Inc Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoidex.
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
AR103624A1 (es) 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
WO2020243590A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease

Also Published As

Publication number Publication date
EP3253382B1 (en) 2021-11-17
EP3253382A4 (en) 2018-10-31
GT201700174A (es) 2018-11-13
EA036404B1 (ru) 2020-11-06
US12337003B2 (en) 2025-06-24
US20220280533A1 (en) 2022-09-08
JP2018504438A (ja) 2018-02-15
CO2017007959A2 (es) 2017-10-31
TN2017000344A1 (en) 2019-01-16
CA2976056A1 (en) 2016-08-11
IL253719A0 (en) 2017-09-28
PH12017501384A1 (en) 2018-01-08
MA40814A1 (fr) 2019-08-30
BR112017016766B1 (pt) 2023-11-07
EP3253382A2 (en) 2017-12-13
DK3253382T3 (da) 2022-02-14
CN107405325A (zh) 2017-11-28
CL2017001983A1 (es) 2018-04-20
ZA201706007B (en) 2019-01-30
AU2021201015A1 (en) 2021-03-11
IL290823A (en) 2022-04-01
US20180008616A1 (en) 2018-01-11
US20220280534A1 (en) 2022-09-08
TW201628625A (zh) 2016-08-16
CA2976056C (en) 2024-02-06
WO2016127019A3 (en) 2016-11-03
AU2016215179B2 (en) 2021-02-25
BR112017016766A2 (pt) 2018-04-10
ES2905872T3 (es) 2022-04-12
PE20180027A1 (es) 2018-01-09
KR20170115071A (ko) 2017-10-16
SG11201706347SA (en) 2017-09-28
CR20170356A (es) 2018-02-28
SV2017005512A (es) 2018-06-12
MX388508B (es) 2025-03-20
ECSP17057848A (es) 2017-10-31
WO2016127019A2 (en) 2016-08-11
EA201791770A1 (ru) 2017-12-29
JP2022000483A (ja) 2022-01-04
AU2016215179A1 (en) 2017-08-24
IL253719B (en) 2022-04-01
JP7306791B2 (ja) 2023-07-11
CL2018003604A1 (es) 2019-02-22
UA125744C2 (uk) 2022-06-01
US11311557B2 (en) 2022-04-26
HK1246191A1 (zh) 2018-09-07
NI201700100A (es) 2018-09-06
EP4035665A1 (en) 2022-08-03
CN107405325B (zh) 2021-11-12
CL2018001006A1 (es) 2018-06-15
MX2017010131A (es) 2017-11-01

Similar Documents

Publication Publication Date Title
AR103624A1 (es) Composiciones farmacéuticas para terapia de combinación
JP2018504438A5 (es)
PE20140572A1 (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
HRP20241674T1 (hr) 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
SG161256A1 (en) Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
PE20151091A1 (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
RU2008146815A (ru) Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол т нестероидный противовоспалительный препарат
ATE394094T1 (de) Tablette enthaltend 3-((2-ä(4- (hexyloxycarbonylamino-imino-methyl)-phenylamin )-methylü-1-methyl-1h-benzimidazol-5-carbonyl)- pyridin-2-yl-amino)-propionsäure-ethylester oder dessen salze
AR097204A1 (es) Métodos de tratamiento de tumores sólidos
DK1485094T3 (da) Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phanylamino]-methyl}-1-methyl-1h-benzimi dazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina
CL2024000756A1 (es) Sal de potasio de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
AR061298A1 (es) Sales de n-hidroxi -3- [4- [ [ [2- (2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2- propenamida.composciones farmaceuticas.
PE20220711A1 (es) Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6)
NZ602125A (en) Uses of dgat1 inhibitors
EA200970398A1 (ru) Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр
HRP20171425T1 (hr) Derivati oksazolidin-2-on-pirimidina
NZ592543A (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
PE20141679A1 (es) Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
UY31385A1 (es) Composicion farmacéutica de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida
PE20081200A1 (es) Sal de potasio cristalina de analogos de lipoxina a4
AR052888A1 (es) Uso del agonista alfa de ppar para preparar una formulacion farmaceutica, paquete y dosis unitaria de dicha formulacion
AR080023A1 (es) Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa
AR082137A1 (es) Derivados de bisaril(tio)morfolina como modulares s1p y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure